Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + Adebrelimab + Chemotherapy in Cisplatin-Ineligible R/M HNSCC
NCT07105592Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab, adebrelimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fudan University. Started May 2025; status: recruiting.
02
Drugs
nimotuzumabadebrelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07105592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105592.